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Background: The relationship between sweat electrolytes and age is uncertain, as is the value of measuring sodium or the chloride:sodium ratio.
Methods: 13,785 sweat tests performed over 23 years at one center through the Macroduct collection in clinically obtained samples were analyzed.
Results: Sweat chloride tended to decrease over the ﬁrst year of life, slowly increase until the fourth decade, then either level off or slightly
decrease. In children, sweat sodium overlapped between those with positive and negative sweat tests, but not in adults. If the sweat test was
positive, there was a higher likelihood of having a chloride:sodium ratio N1, but most subjects with a ratio N1 did not have CF.
Conclusions: Sweat chloride and sodium vary with age. Measurement of sweat sodium did not add discriminatory value. The proportion of
subjects with a chloride:sodium ratio N1, with or without CF, varied greatly between age ranges.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Sweat; Electrolytes; Newborn screening1. Introduction
1.1. Background
Patients with cystic fibrosis (CF) have reduced chloride
transport and thus elevated sweat chloride levels, due to defects
in the cystic fibrosis transmembrane conductance regulator
(CFTR) chloride channel. Despite advances in genetic testing,
the sweat chloride test remains the gold standard for the
diagnosis of CF [1–4]. It has excellent sensitivity and
specificity, but like any laboratory test, the results are
sometimes ambiguous and confusing [1]. The most recent CF⁎ Corresponding author at: New York Medical College, Department of Pediatrics,
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considers a sweat chloride concentration ≥60 mmol/L as
indicative of CF. CF is considered unlikely if the level is
b29 mmol/L up to six months of age and ≤39 mmol/L for
older patients [1]. Patients with intermediate values may have
CF and the diagnosis must be made by other means, including
DNA analysis and ancillary tests. Patients with CF also have
poor sodium conductance, and thus elevated sweat sodium
levels, because ENaC (epithelial Na+ channel) activity is in part
dependent on CFTR activity [5]. Current guidelines do not
recommend the use of sweat sodium concentration for the
diagnosis of CF. However, some laboratories use this value for
quality control purposes because sweat chloride and sodium
tend to be similar [3,4]. Further, some, but not all studies
suggest that the ratio of chloride to sodium is often different in
patients with CF [6–8] and could therefore provide additional
information when analyzing sweat tests with intermediate
chloride concentrations.by Elsevier B.V. All rights reserved.
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and the average age at diagnosis is decreasing. Screening tests
usually require confirmation with a sweat test, but normal
reference ranges are not well established for young infants [1].
The diagnosis of CF is also increasingly being made in adults,
as mild phenotypes are being recognized. Sweat electrolyte
concentrations have been reported to gradually increase with
age [7,9], and normal (non-CF) subjects may have sweat
chloride concentrations between 60 and 80 mmol/L [10]. To
complicate the interpretation, those diagnosed with CF as
adults tend to have lower sweat chloride levels than those
diagnosed as children [11].
While there are some recent publications, most published
data on normal sweat electrolytes were obtained over forty
years ago. Nearly all prior reference ranges were obtained from
sweat collected on gauze or filter paper [12], while many
laboratories, including ours, use the Macroduct® coil for
collection, which requires a significantly smaller volume of
sweat [1]. It appears that the use of this collection system may
lead to a smaller proportion of sweat samples obtained in
infants that must be discarded due to “quantity insufficient”
results [13]. The laboratory at our institution is accredited by
the CFF and has been logging all sweat test results for over
twenty years. We report a retrospective analysis of this data.
The aims of this study were to assess how sweat chloride varies
with age and whether any additional information can be
obtained from either the measurement of sweat sodium or the
chloride:sodium ratio.
2. Subjects and methods
This study was approved by our institutional review board.
All sweat tests were performed at Westchester Medical Center,
stimulated and collected via the Macroduct® coil method
(Wescor Inc., Logan, Utah) with a standardized methodology
of iontophoresis [14] following CFF guidelines [22]. Sweat
chloride values were determined by a chloridometer and sweat
sodium by flame photometry. These methods did not change
during the course of this study. Besides the values of the sweat
electrolytes, the following information were collected on all
subjects in handwritten log books: name, age, sex, medical
record number, indication for test, and presence of family
history of CF.
The records of all patients tested during the years 1986
through 2009 were transcribed from these handwritten logs
onto a computer spreadsheet (Excel, Microsoft Corporation).
Each subject's date of birth was independently confirmed with
data from the hospital's computerized medical records.
Subjects whose date of birth could not be verified were
excluded from further analysis. When subjects had multiple
measures of the same electrolyte simultaneously performed at
more than one body site during a single session, as recom-
mended by the CFF [1], results were averaged for purposes of
this analysis.
Descriptive statistics including numbers of observations,
means, medians, minimums, maximums, and standard devia-
tions were used to summarize continuous format variables.95% confidence intervals were calculated for proportions.
Three age groups were analyzed: birth to less than 6 months,
6 months to less than 18 years, and 18 years or greater.
Chi-square or analysis of variance (ANOVA) was used to
compare for differences among the three age groups, depending
on whether they were categorical or continuous variables.
Correlation analysis (Pearson and Spearman) and linear
regression were used to test if there was a relationship between
sweat electrolytes and age. Correlation coefficients and
associated p-values are reported. Differences between subjects
likely to have CF and not likely to have CF were compared
with two-sample tests. All tests were two-sided and p-values
less than 0.05 were considered statistically significant. Unless
specified otherwise, data are shown as mean ± SD.
3. Results
The initial sample included 14,392 sweat testing sessions
representing 13,502 individual subjects. Of these, 159 (1.1%)
were excluded from further analysis due to the inability to
confirm the exact age at the time of the test. A further 450
(3.1%) were excluded because the collected volume was less
than 15 μL [1,15]. Of these, 296 were greater than 3 months of
age, representing 2.3% of subjects in that age range, consistent
with CFF's operational criteria for sweat test laboratories [1];
and 154 were less than 3 months of age, representing 10.8% of
subjects in that age range.
The remaining study population consisted of 13,785 testing
sessions. Clinical indication(s) for having the sweat test
performed was noted in 13,468 (98%) of these sessions.
Indications were (N, % of total): respiratory symptoms (9535,
69%), gastrointestinal symptoms (2701, 19%), failure to thrive
(702, 5%), both respiratory and gastrointestinal symptoms (406,
4%), positive newborn screen for CF (1017, 7%), rectal prolapse
(53, 0.4%), nasal polyps (30, 0.2), family history of CF (778,
6%), and repeat testing for confirmation of a positive test or
because the previous test did not yield a sufficient volume of
sweat for proper testing (830, 6%). There were no clinically
significant differences in mean sweat chloride (range 12.1–13.2)
or mean sweat sodium (range 15.6–18.6) among the various
clinical indications. Also, there was no clinically significant
difference in sweat chloride or sodium before and after 2002,
the year that newborn screening for CF was initiated in the state
of New York (chloride was 13.0 ± 13.5 mmol/L before
2002 versus 12.3 ± 10.8 mmol/L after 2002, and sodium was
18.7 ± 15.4 mmol/L before 2002 versus 19.5 ± 14.1 8 mmol/L
after 2002).
Subjects ranged in age from 5 days to 78.6 years, with a
mean age of 3.95 years. 11,106 (80.8%) were between
6 months and 18 years, 2377 (17.3%) were less than 6 months,
and 292 (2.1%) were 18 years or older. 79 subjects were
40 years of age or more. There were 8175 males (59.3%) and
5610 females (40.7%). Sample volume showed a statistically
significant increase with age (p b 0.0001 by ANOVA) al-
though there was much overlap and the magnitude was not to
a degree where there was a clinically significant difference
among our three age groups. The mean sample volume was
Table 1
Distribution of subjects based on age and the CFF guidelines' clinical
classification of sweat test results.
Clinical
classification
b6 months 6 months to
b18 years
≥18 years Total
Negative 2214 (93.1%) 10,760 (96.9%) 204 (69.9%) 13,178 (95.7%)
Intermediate 41 (1.7%) 196 (1.8%) 47 (16.1) 284 (2.1%)
Positive 122 (5.1%) 150 (1.4%) 41 (14.0%) 313 (2.3%)
Total 2377 (100%) 11,106 (100%) 292 (100%) 13,775 (100%)
Displayed percentages are tallied vertically.
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41.8 ± 24.6 in those aged b6 months, 56.8 ± 25.3 in those
aged 6 months to b18 years, and 51.5 ± 25.3 for those aged
N18 years. Mean volume for females (50.6 ± 23.6 μL) was
lower than for males (58.0 ± 38.8 μL), p b 0.0001.
Table 1 shows sweat test results based on age and the clinical
classifications recommended by the CFF [1]. While the majority
of subjects in all age groups were negative, the percent of
subjects with positive tests was significantly greater (p b 0.0001)
in subjects ≥18 years of age than younger subjects. Mean
sweat chloride concentration was 13.9 ±15.2 mmol/L (95%
CI: 13.6–14.2) with a range of 1 to 159 mmol/L. There were
313 subjects (2.3%) with sweat chlorides ≥60 mmol/L. The
oldest patient with a positive sweat test was 60 years old. Although
there was much overlap, the mean sweat chloride was higher for
females, 14.3 ± 14.9, versus 13.6 ± 15.3 for males, p = 0.02.
The relationship between sweat chloride and age is
demonstrated in Fig. 1. There was a tendency for the sweat
chloride to decrease during the first year of life (Spearman's
r = −0.16, p b 0.0001). Sweat chloride tended to gradually
increase in children aged 6 months to 18 years (Spearman's
r = 0.28, p b 0.0001). Sweat chloride tended to gradually
increase in adults ≥18 years of age (Spearman's r = 0.30,
p b 0.0001). Though the sample size was small, it appears that
sweat chloride peaked between 30 and 40 years of age, and
either leveled off or decreased after age 40. The correlation
between age and sweat chloride is considered statistically weak
(r b 0.4) for all three age groups.Fig. 1. Variation in sweat chloride with age. Circles: means; triangles: means + 1SD
concentrations that define the boundaries between the three CF Foundation referenc
intermediate sweat tests, and the lower (dotted) line (at 30 mmol/L up to 6 months o
intermediate sweat tests from those unlikely to have CF.The relationship between chloride, sodium, age groups, and
CFF recommended clinical classification [1] is shown in Table 2
[note: the p-values for all rows and columns were b0.0001]. The
correlation between sweat sodium and age (Spearman's r = 0.48,
p b 0.0001) was of moderate strength (generally expressed as r in
the range of 0.4–0.7). Sodium was higher (94.0 ± 20.2 mmol/L)
in subjects with positive sweat tests than those with intermediate
(60.0 ± 13.6 mmol/L) or negative tests (17.8 ± 11.2 mmol/L)
(r2 = 0.54, p b 0.0001 for all three groups). Among adults, there
was no overlap in sweat sodium levels between those with
positive sweat tests and those with negative tests, but this did not
hold true for younger subjects. Similar to sweat chloride, sweat
sodium was higher in females, 21.1 ± 17.0 mmol/L, than for
males, 19.8 ± 17.0 mmol/L (p b 0.001). The correlation between
sweat chloride and sodium (r = 0.89, p b 0.0001) was strong
(as expressed by an r N0.7).
The mean chloride:sodium ratio gradually decreased from
0.83 ± 0.44 for those less than 6 months of age, to 0.71 ± 0.74
for subjects aged 6 months to 18 years, and to 0.66 ± 0.49 for
subjects 18 years of age or older. The chloride:sodium ratio
was N1 in 15.0% of all subjects (95% CI:14.4–15.6%) and
53.6% (95% CI: 47.7–59.4%) in patients with sweat tests
diagnostic for CF. However, only 7.8% (95% CI: 6.7–9.1%) of
subjects with a chloride:sodium ratio N1 had a positive sweat
test.4. Discussion
The Cystic Fibrosis Foundation stated that “Optimal
outcomes in CF depend on timely and accurate diagnosis”
[1]. With the proliferation of newborn screening, sweat tests are
being increasingly performed on younger children. Also, with
increased awareness of milder variants of CF, sweat tests are
often performed on adults with atypical symptoms. In order to
address these issues, we present the largest population based
study reported to date.
The CFF Consensus Statement on the Diagnosis of CF states
that there is a need to further investigate whether infants under
3 months of age are at greater risk for insufficient sweat volume; squares: means + 2SD. The overlaid horizontal lines demarcate the chloride
e ranges: the upper (dashed) line (at 60 mmol/L) separates those with CF from
f age and at 40 mmol/L for those aged 6 months and older) separates those with
Table 2
Sweat chloride and sodium concentrations [mmol/L], and number (%) of subjects and with sweat chloride:sodium ratio N1.
Clinical classification b6 months 6 months to b18 years ≥18 years Total
Negative Chloride 9.1 ± 4.7 11.6 ± 6.9 18.9 ± 9.4 11.3 ± 6.8
Sodium 12.8 ± 7.6 18.5 ± 11.2 33.8 ± 15.7 17.8 ± 11.2
Cl:Na N1 495 (23.7%) 1321 (12.6%) 7 (3.5%) 1823 (14.2%)
Intermediate Chloride 40.5 ± 9.0 46.9 ± 5.6 45.8 ± 5.3 45.8 ± 6.5
Sodium 45.1 ± 14.9 61.1 ± 11.7 67.3 ± 11.3 60.0 ± 13.6
Cl:Na N1 12 (34.3%) 14 (7.5%) 0 (0.0%) 26 (9.8%)
Positive Chloride 96.9 ± 14.6 95.5 ± 18.9 89.1 ± 19.7 95.2 ± 17.6
Sodium 88.1 ± 18.1 96.4 ± 20.8 101.4 ± 19.1 94.0 ± 20.2
Cl:Na N1 82 (75.9%) 68 (46.9%) 7 (17.5%) 157 (53.6%)
Total Chloride 14.2 ± 20.5 13.3 ± 12.9 33.1 ± 27.0 13.9 ± 15.2
Sodium 16.9 ± 18.6 20.3 ± 15.5 48.5 ± 29.1 20.3 ± 17.0
Cl:Na N1 589 (26.3%) 1403 (12.9%) 14 (4.9%) 2006 (15.0%)
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there is a relatively high percentage of infants less than
3 months old that have an insufficient volume of sweat
collected.
Consistent with previous reports, sweat chloride values in this
study population tended to decrease during the first year of life
[17,18], and then increase with subsequent aging [1,7,19]; though
we found that the correlation was relatively weak in all age
groups. Sweat chloride concentration appears to peak during
middle age followed by a decrease in older age; though this
observation may be an artifact reflective of the relatively small
number of elderly subjects tested. This data suggests that a lower
limit of 60 mmol/L to define CF may be insufficiently sensitive
for all age groups. Given the demonstrated “dip” in sweat
chloride during early childhood, the cutoff of 60 mmol/L may be
too high above the 2SD values in this age range, and thus result in
an increased number of patients with ambiguously low or
intermediate test results. Conversely, among adults, a 60 mmol/L
cutoff lies relatively low, right across the 1SD values; and a cutoff
for “unlikely to have CF” of 40 mmol/L lies just above the mean
chloride values for this group. This may result in low specificity
and increase the number of subjects with ambiguously high test
results. This latter finding supports those of Hall et al. [7], who
found that a significant number of non-CF adults had sweat
chloride values greater than 60 mmol/L.
Our findings with regard to sweat sodium values and changes
with age are similar to those of Kirk and Westwood [9] and we
agree with Kirk et al.'s subsequent findings [19] that measure-
ment of sweat sodium did not add to the discriminatory value of
the sweat test. Infants tended to have a higher chloride:sodium
ratio, regardless of whether they have CF or not, and a
greater proportion of subjects with positive sweat tests had
a chloride:sodium ratio N1 than subjects with negative
sweat tests in all ranges, as previously suggested [6,19].
However, differences between age ranges in this proportion
were remarkable. Among those with a positive sweat test, the
chloride:sodium ratio was N1 in most subjects less than those
6 months of age, about half of those 6 months to 18 years of age,
and in less than 20% of those 18 years of age or greater, although
the sample size in adults was relatively small. Furthermore, lessthan 10% of subjects with a chloride:sodium ratio N1 had positive
sweat tests.
Strengths of this study include a large number of subjects,
the nature of the data collection, the technical methodology of
performing the sweat tests, and the measurement of several
electrolytes. All sweat tests in this report utilized the
Macroduct® collection system rather than the older Gibson
and Cooke method that utilized either gauze or filter paper for
collection. While sweat chloride concentrations have been
reported to be highly correlated between the two methods, there
are occasional discrepancies for individual patients [20–22].
The main weakness of this study, as with previous studies [12],
is that we did not study healthy control subjects and therefore are
not suggesting that our data be used as reference intervals. Subjects
had sweat tests because their physicians referred them for possible
CF, either due to the presence of symptoms, a positive newborn
screening test result, or positive family history. Therefore it is
possible that there are patients with negative sweat tests who have
CF, albeit with “mild” mutations [23–28]. Another limitation is
that the diagnosis of CF could not be confirmed by means
independent of the sweat test. Because of the regional nature of our
tertiary care center, many patients with positive sweat tests have
not been followed here. Also, given the large number of subjects
and the long time span over which this data was collected,
verification with clinical findings and genetic information was not
possible. Also, as is doubtlessly occurring in many other labs,
there is also a sampling bias that differs between young and old
subjects based on the referral pattern to the sweat lab: more
non-CF children are undergoing sweat chloride testing than
non-CF adults due to the referral practice wherein the use of sweat
chloride in diagnostic tests is underutilized in adults. Reassuringly,
our results are consistent with reference values recently reported
by Mishra et al. [29], where in order to achieve a cleaner control
group they studied a smaller sample size (n = 300), but on whom
they performed a history focusing on pertinent symptoms and
family history and screened for the delF508 mutation on selected
subjects. Their data set did not include infants (study population
age range was 5 to 68 years), but otherwise both studies have
similar results for values of sweat chloride, sweat sodium, and the
ratio between these two electrolytes.
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year of life and then slowly increases with age. It appears that
chloride concentration may peak in middle age and trend
downward after that, but more studies with larger sample sizes
in older adults are needed to confirm that finding. As shown in
the figure, perhaps sweat chloride reference ranges for defining
CF should be further subdivided into additional age groups than
just the two in the current CFF guidelines. There are significant
differences in the relationship between sweat chloride and
sodium in relation to age and CFF recommended clinical
classification [1]; however the measurement of sweat sodium
did not add to the discriminatory value of the sweat test.Acknowledgments
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